PDS Biotechnology (PDSB) 10-K2022 FY Annual report

Filed: 28 Mar 23, 5:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abstr, AEs, affirm, affirmed, altogether, bankruptcy, bar, beneficiary, Big, Bioeconomy, Biomanufacturing, biomarker, black, breakthrough, Bright, Brown, BTIG, budgetary, Cadillac, Catalyst, ceiling, chart, check, circuit, cited, clarification, clearance, climate, Clin, closure, Coast, collateral, commodity, composed, conflict, consumption, contraindication, convention, convey, conveyance, counterparty, CR, creation, CT, ctHPV, customer, cytotoxic, debarment, deferral, detention, DHA, diligence, diligent, disabled, dispending, disposition, Division, DMC, DoD, downturn, dug, easily, effectuated, Eleventh, Emission, encumber, energy, equitable, excise, explanation, expressly, EYASU, faith, fashion, fast, faster, FCP, FDASIA, FDIC, FIGO, formula, foster, fragmented, FSS, FV, Granzyme, guarantor, Henson, hereunder, hinder, honor, Horizon, ICI, ID, IEC, IIT, image, imaging, IMM, Immunopharmacology, inconvenient, indemnify, Indian, inhaled, insolvency, insolvent, instilled, interleukin, interstate, invasion, IRA, IRC, irreversible, Jon, Kaplan, lethal, loan, longevity, longstanding, MAA, magnify, marker, match, matched, matching, meant, Meier, Merk, methodology, military, mimicking, mislabeling, month, Moonshot, mucin, multifunctional, NDA, necrotic, Neil, NIAID, nineteen, NK, nonrenewal, Oncol, opportunistically, OS, outpace, overpayment, overseen, papilloma, Peak, penalize, penalty, perpetual, PET, placebo, placement, Positron, poster, poverty, Powerscourt, PPACA, predetermined, premium, prepay, prepayment, provoke, qualification, rarity, reapprove, Reauthorization, receivership, redundant, relaxation, remanded, repay, repurchasing, Rescue, resume, retail, revocation, revoke, Riley, Russia, screening, SD, seize, seizure, Sequestration, shipment, shrinking, signature, signify, Silicon, Silvergate, SITC, SK, Spencer, Stable, statutorily, streamline, substance, sum, suppl, SVB, swept, Taxpayer, thought, threshold, tighter, Tomography, Toney, TR, TRICARE, tying, Ukraine, unanticipated, unblinded, uncommitted, undrawn, unexpired, unidentified, uninsured, unplanned, unreasonable, unsafe, untitled, VA, Valley, venture, verify, Virology, wage, waiting, Wigginton, XXV

Removed: acting, adapt, adequately, adjuvant, aggressive, assignment, attribute, authorize, began, beneficially, Berkeley, bona, CHF, clear, conditioned, Connell, content, correction, directing, emergency, extremely, Farmacore, fide, Figure, gather, invention, investigated, issuable, minimized, modestly, moiety, monitored, obstacle, oral, path, recession, safer, salary, Senate, servicing, shorter, strain, strongest, sun, Turnpike, twenty, undertaken, unwilling, vest, welfare, Wuhan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PDSB transcripts

PDSB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Annual Report of PDS Biotechnology Corporation (the “Company”), on Form 10-K for the year ended December 31, 2022 (the “Report”), I, Matthew Hill, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that:

(1)

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 28, 2023	/s/ Matthew Hill
	Matthew Hill
	Chief Financial Officer
	(Principal Financial and Accounting Officer)